Sigilon Therapeutics, Inc. (SGTX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Rogerio Vivaldi Coelho
Employees:
96
100 BINNEY STREET, STE 600, CAMBRIDGE, MA 02142
617-336-7540

We are a clinical-stage biotechnology company pioneering a new class of therapeutics and seeking to develop functional cures for patients with chronic diseases by providing stable and durable levels of therapeutic molecules to patients.

Data derived from most recent annual or quarterly report
Market Cap 26.859 Million Shares Outstanding32.361 Million Avg 30-day Volume 192.626 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.54
Price to Revenue4.8511 Debt to Equity0.3119 EBITDA-69.217 Million
Price to Book Value0.7365 Operating Margin-719.4167 Enterprise Value-35.641 Million
Current Ratio2.96 EPS Growth0.596 Quick Ratio2.785
1 Yr BETA 1.3661 52-week High/Low 11.79 / 0.73 Profit Margin-736.2533
Operating Cash Flow Growth-8.8268 Altman Z-Score-3.1307 Free Cash Flow to Firm -60.717 Million
Earnings Report2022-08-10
View SEC Filings from SGTX instead.

View recent insider trading info

Funds Holding SGTX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SGTX BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-06-23:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2022-05-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-14:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-02-22:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-12-13:
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-29:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-08-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-07-09:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-06-28:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    OESTERLE STEPHEN N.

    8,888 2022-05-26 1

    RUFFOLO ROBERT R

    8,888 2022-05-26 2

    COLE DOUGLAS G.

    8,888 2022-05-26 1

    COX JOHN

    8,888 2022-05-26 1

    SHAFF ERIC D.

    8,888 2022-05-26 1

    PATEL KAVITA

    8,888 2022-05-26 1

    STORY BROOKE

    8,888 2022-05-26 1

    YUAN QING SARAH CTOO

    120,000 2022-04-01 2

    VIVALDI COELHO ROGERIO PRESIDENT AND CEO

    230,000 2022-02-18 2

    ASHTON-RICKARDT PHILIP CHIEF SCIENTIFIC OFFICER

    90,000 2022-02-18 3

    PONTES JOSIAS ACTING CHIEF FINANCIAL OFFICE

    60,000 2022-02-18 2

    ORFALI MAY CHIEF MEDICAL OFFICER

    10,000 2022-02-18 4

    ANDERSON DANIEL GRIFFITH

    2,022,222 2021-06-02 0

    REICIN GLENN CHIEF FINANCIAL OFFICER

    0 2021-02-11 0

    SMITH DEVYN CHIEF OPERATING OFFICER

    0 2021-02-11 0

    CORZO DEYA CHIEF MEDICAL OFFICER

    0 2021-02-11 0

    ELI LILLY & CO

    • 10% Owner
    No longer subject to file 2020-12-08 0

    FLAGSHIP VENTURES FUND V GENERAL PARTNER LLC

    FLAGSHIP VENTURES FUND V, L.P.

    FLAGSHIP PIONEERING SPECIAL OPPORTUNITIES FUND II, L.P.

    FLAGSHIP PIONEERING SPECIAL OPPORTUNITIES FUND II GENERAL PARTNER LLC

    FLAGSHIP PIONEERING INC.

    AFEYAN NOUBAR

    • 10% Owner
    10,370,369 2020-12-08 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    SHAFF ERIC D.

    2022-05-27 17:01:28 -0400 2022-05-26 A 8,888 a 8,888 direct

    RUFFOLO ROBERT R

    2022-05-27 17:00:47 -0400 2022-05-26 A 8,888 a 8,888 direct

    PATEL KAVITA

    2022-05-27 17:01:07 -0400 2022-05-26 A 8,888 a 8,888 direct

    OESTERLE STEPHEN N.

    2022-05-27 17:01:00 -0400 2022-05-26 A 8,888 a 8,888 direct

    STORY BROOKE

    2022-05-27 17:00:32 -0400 2022-05-26 A 8,888 a 8,888 direct

    COLE DOUGLAS G.

    2022-05-27 17:00:30 -0400 2022-05-26 A 8,888 a 8,888 direct

    COX JOHN

    2022-05-27 17:00:45 -0400 2022-05-26 A 8,888 a 8,888 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    SIGILON THERAPEUTICS INC SGTX 2022-06-29 22:15:03 UTC -0.3012 1.8712 150000
    SIGILON THERAPEUTICS INC SGTX 2022-06-29 21:45:05 UTC -0.3012 1.8712 150000
    SIGILON THERAPEUTICS INC SGTX 2022-06-29 21:15:03 UTC -0.3012 1.8712 150000
    SIGILON THERAPEUTICS INC SGTX 2022-06-29 20:45:03 UTC -0.3012 1.8712 150000
    SIGILON THERAPEUTICS INC SGTX 2022-06-29 20:15:04 UTC -0.3012 1.8712 150000
    SIGILON THERAPEUTICS INC SGTX 2022-06-29 19:45:03 UTC -0.3012 1.8712 150000
    SIGILON THERAPEUTICS INC SGTX 2022-06-29 19:15:04 UTC -0.3012 1.8712 150000
    SIGILON THERAPEUTICS INC SGTX 2022-06-29 18:45:03 UTC -0.3012 1.8712 150000
    SIGILON THERAPEUTICS INC SGTX 2022-06-29 18:15:03 UTC -0.3012 1.8712 150000
    SIGILON THERAPEUTICS INC SGTX 2022-06-29 17:45:03 UTC -0.3012 1.8712 150000
    SIGILON THERAPEUTICS INC SGTX 2022-06-29 17:15:03 UTC -0.3012 1.8712 150000
    SIGILON THERAPEUTICS INC SGTX 2022-06-29 16:45:03 UTC -0.2197 1.7897 150000
    SIGILON THERAPEUTICS INC SGTX 2022-06-29 16:15:03 UTC -0.2197 1.7897 150000
    SIGILON THERAPEUTICS INC SGTX 2022-06-29 15:45:03 UTC -0.2197 1.7897 150000
    SIGILON THERAPEUTICS INC SGTX 2022-06-29 15:15:03 UTC -0.2197 1.7897 150000
    SIGILON THERAPEUTICS INC SGTX 2022-06-29 14:45:03 UTC -0.2197 1.7897 150000
    SIGILON THERAPEUTICS INC SGTX 2022-06-29 14:15:03 UTC -0.2197 1.7897 150000
    SIGILON THERAPEUTICS INC SGTX 2022-06-29 13:45:03 UTC 0.3395 1.2305 150000
    SIGILON THERAPEUTICS INC SGTX 2022-06-29 13:15:03 UTC 0.3395 1.2305 150000
    SIGILON THERAPEUTICS INC SGTX 2022-06-29 12:45:02 UTC 0.3395 1.2305 150000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments